Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 4/20 | 0.60 |
| ▸ | SI | P14410 | 2/20 | 0.55 |
| ▸ | GBA1 | P04062 | 2/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | LRAT | O95237 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11044942 | 0.96 | FUCA1 (0.63) | FUCA1SIGBA1MGAMGAA | |
| SCHEMBL18460913 | 0.96 | FUCA1 (0.63) | FUCA1SIGBA1MGAMGAA | |
| SCHEMBL21105130 | 0.96 | FUCA1 (0.63) | FUCA1SIGBA1MGAMGAA | |
| SCHEMBL133955 | 0.96 | FUCA1 (0.63) | FUCA1SIGBA1MGAMGAA | |
| SCHEMBL5805992 | 0.93 | — | — | |
| SCHEMBL11049253 | 0.85 | — | — | |
| Carbamic Acid SCHEMBL6209325 | 0.82 | FUCA1 (0.50) | FUCA1SIGBA1MGAMGAA | |
| SCHEMBL29379044 | 0.80 | FUCA1 (0.55) | FUCA1SIGBA1MGAMGAA | |
| SCHEMBL374134 | 0.80 | FUCA1 (0.55) | FUCA1SIGBA1MGAMGAA | |
| SCHEMBL21105031 | 0.79 | GBA1 (0.50) | FUCA1SIGBA1MGAMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6967242-B2 | Antimicrobial 2-deoxystreptamine compounds | ISIS PHARMACEUTICALS, INC. (US) | 2005-11-22 | — | — | US | disclosed |
| US-20030109461-A1 | Antimicrobial 2-deoxystreptamine compounds | ISIS PHARMACEUTICALS, INC. | 2003-06-12 | — | — | US | disclosed |
| US-6541456-B1 | Analogs of aminoglycoside compounds of the class having a glycosylated 2-deoxystreptamine ring as well as their preparation and use as prophylactic or therapeutics against microbial infection. | ISIS PHARMACEUTICALS, INC. | 2003-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109461-A1 | Antimicrobial 2-deoxystreptamine compounds | DUT, GNE, ST6GAL1 | FUCA1 452/4885SI 235/4885GBA1 607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.